Oligodendrocyte pathophysiology: A new view of schizophrenia

International Journal of Neuropsychopharmacology

Volumn 10, Issue 4, 2007, Pages 503-511

  Segal, Devorah ^a   Koschnick, Jessica R ^a   Slegers, Linda H A ^a   Hof, Patrick R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Myelin; Myelin associated glycoprotein (MAG); Oligodendrocytes; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ARTICLE; DIFFUSION TENSOR IMAGING; FRONTAL LOBE; GENE; GENE EXPRESSION; HUMAN; IMAGING; MICROARRAY ANALYSIS; MYELIN DEFICIENCY; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; WHITE MATTER;

ANIMALS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, KNOCKOUT; MYELIN SHEATH; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; RECEPTORS, CELL SURFACE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SIGNAL TRANSDUCTION;

EID: 34250871660     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570600722X     Document Type: Article

References (59)

1. Aberg K, Saetre P, Jareborg N, Jazin E (2006). Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proceedings of the National Academy of Sciences USA 103, 7482-7487.
2. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney Jr. WE, Jones EG (1996). Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. Journal of Neuroscience 16, 19-30.
3. Aston C, Jiang L, Sokolov BP (2005). Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Molecular Psychiatry 10, 309-322.
4. Bergles DE, Roberts JDB, Somogyi P, Jahr CE (2000). Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature 405, 187-191.
5. Bongarzone ER, Howard SG, Schonmann V, Campagnoni AT (1998). Identification of the dopamine D3 receptor in oligodendrocyte precursors: potential role in regulating differentiation and myelin formation. Journal of Neuroscience 18, 5344-5353.
6. Bouras C, Kovari E, Riederer BM, Hof PR, Giannakopoulos P (2001). Morphological alteration in the anterior cingulate cortex in drug-naïve patients with schizophrenia and bipolar disorder. Acta Neuropathologica 102, 373-379.
7. Buchsbaum MS, Tang CY, Peled S, Gudbjartsson H, Lu D, Hazlett EA, Downhill J, Haznedar M, Fallon JH, Atlas SW (1998). MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. Neuroreport 9, 425-430.
8. Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V (2006). Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophrenia Research 85, 245-253.
9. Chambers JS, Perrone-Bizzozero NI (2004). Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochemical Research 29, 2293-2302.
10. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V (2003). White matter changes in schizophrenia: evidence for myelin-related dysfunction. Archives of General Psychiatry 60, 443-456.
11. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V (2006). Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiology of Disease 21, 531-540.
12. Dracheva S, Marras SAE, Elhakem SL, Kramer FR, Davis KL, Haroutunian V (2001). N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. American Journal of Psychiatry 158, 1400-1410.
13. Duan H, Wearne SL, Rocher AB, Macedo A, Morrison JH, Hof PR (2003). Age-related dendritic and spine changes in corticocortically projecting neurons in macaque monkeys. Cerebral Cortex 13, 950-961.
14. Foong J, Maier M, Barker GJ, Brocklehurst S, Miller DH, Ron MA (2000). In vivo investigation of white matter pathology in schizophrenia with magnetization transfer imaging. Journal of Neurology, Neurosurgery and Psychiatry 68, 70-74.
15. Foong J, Symms MR, Barker GJ, Maier M, Woermann FG, Miller DH, Ron MA (2001). Neuropathological abnormalities in schizophrenia: evidence from magnetization transfer imaging. Brain 124, 882-892.
16. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. American Journal of Psychiatry 157, 1141-1149.
17. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, Barnes TR, Hirsch SR (1998). Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. Journal of Neurology, Neurosurgery and Psychiatry 65, 446-453.
18. Glantz LA, Lewis DA (2000). Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Archives of General Psychiatry 57, 56-73.
19. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA (2001). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences USA 98, 4746-4751.
20. Hof PR, Haroutunian V, Friedrich Jr. VL, Byne W, Buitron C, Perl DP, Davis KL (2003). Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biological Psychiatry 53, 1075-1085.
21. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, Kato T (2005). DNA methylation status of SOX10 correlated with its downregulation and oligodendrocyte dysfunction in schizophrenia. Journal of Neuroscience 25, 5376-5381.
22. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama Y, Yoshikawa T, Kato T (2006). A family-based and case-control association study of SOX10 in schizophrenia. American Journal of Medical Genetics 141B, 477-481.
23. Kaiser S, Foltz LA, George CA, Kirkwood SC, Bemis KG, Lin X, Gelbert LM, Nisenbaum LK (2004). Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiology of Disease 16, 220-235.
24. Kalus P, Muller TJ, Zuschratter W, Senitz D (2000). The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients. Neuroreport 11, 3621-3625.
25. Katsel P, Davis KL, Haroutunian V (2005). Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophrenia Research 79, 157-173.
26. Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, Niznikiewicz M, Connor EE, Levitt JJ, Frumin M, et al. (2005). DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity. Neuroimage 15, 1109-1118.
27. Kubicki M, Westin CF, Nestor PG, Wible CG, Frumin M, Maier SE, Kikinis R, Jolesz FA, McCarley RW, Shenton ME (2003). Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biological Psychiatry 54, 1171-1180.
28. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA (2003). Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nature Genetics 33, 366-374.
29. Levine JM, Reynolds R, Fawcett JW (2001). The oligodendrocyte precursor cell in health and disease. Trends in Neuroscience 24, 39-47.
30. Li C, Tropak MB, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B, Peterson A, Roder J (1994). Myelination in the absence of myelin-associated glycoprotein. Nature 369, 747-750.
31. Lim KO, Hedehus M, Moseley M, de Crespigny A, Sullivan EV, Pfefferbaum A (1999). Compromised white matter integrity in schizophrenia inferred from diffusion tensor imaging. Archives of General Psychiatry 56, 367-374.
32. Liu X, Qin W, He G, Yang Y, Chen Q, Zhou J, Li D, Gu N, Xu Y, Feng G, et al. (2005). A family-based association study of the MOG gene with schizophrenia in the Chinese population. Schizophrenia Research 73, 275-280.
33. MacDonald ML, Naydenov A, Chu M, Matzilevich D, Konradi C (2006). Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disorders 8, 255-264.
34. Matute C (2006). Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends in Molecular Medicine 44, 289-292.
35. Matute C, Sanchez-Gomez M, Martinez-Millan L, Miledi R (1997). Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proceedings of the National Academy of Sciences USA 94, 8830-8835.
36. McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP (1998). Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainite receptor-mediated excitotoxicity. Nature Medicine 4, 291-297.
37. McInnes LA, Lauriat TL (2006). RNA metabolism and dysmyelination in schizophrenia. Neuroscience and Biobehavioral Reviews 30, 551-561.
38. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53-67.
39. Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthmann H, Karthigasan J, Kirschner DA, Wintergerst ES, Nave KA, et al. (1994). Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 13, 229-246.
40. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 52, 998-1007.
41. Pan B, Fromholt SE, Hess EJ, Crawford TO, Griffin JW, Sheikh KA, Schnaar RL (2005). Myelin-associated glycoprotein and complementary axonal ligand, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Experimental Neurology 195, 208-217.
42. Peirce TR, Bray NJ, Williams NM, Norton N, Moskovina V, Preece A, Haroutunian V, Buxbaum JD, Owen MJ, O'Donovan MC (2006). Convergent evidence for 2′,3′-cyclic nucleotide 3′phosphodiesterase as a possible susceptibility gene for schizophrenia. Archives of General Psychiatry 63, 18-24.
43. Pierri JN, Volk CLE, Auh S, Sampson A, Lewis DA (2001). Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Archives of General Psychiatry 58, 466-473.
44. Rajkowska G, Selemon LD, Goldman-Rakic PS (1998). Neuronal and glial somal size in the prefrontal cortex. A postmortem morphometric study of schizophrenia and Huntington disease. Archives of General Psychiatry 55, 215-224.
45. Rosin C, Colombo S, Calver AA, Bates TE, Skaper SD (2005). Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia 52, 336-343.
46. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz WF (2004). Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biological Psychiatry 56, 41-45.
47. Selemon LD, Goldman-Rakic PS (1999). The reduced neuropil hypothesis: a circuit-based model of schizophrenia. Biological Psychiatry 45, 17-25.
48. Selemon LD, Rajkowska G, Goldman-Rakic PS (1995). Abnormally high neuronal density in the schizophrenic cortex. Archives of General Psychiatry 52, 805-818.
49. Selemon LD, Rajkowska G, Goldman-Rakic PS (1998). Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional stereologic counting method. Journal of Comparative Neurology 392, 402-412.
50. Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C, Nakamura R, Kakita A, Takahashi H, Nawa H (2004). Prefrontal abnormality of schizophrenia revealed by DNA microarray. Annals of the New York Academy of Science 1025, 84-91.
51. Sun Z, Wang F, Cui L, Breeze J, Du X, Wang X, Cong Z, Zhang H, Li B, Hong N, Zhang D (2003). Abnormal anterior cingulum in patients with schizophrenia: a diffusion tensor imaging study. Neuroreport 14, 1833-1836.
52. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, et al. (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. American Journal of Psychiatry 159, 1944-1946.
53. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S (2003). Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362, 798-805.
54. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V (2001). Electron microscopy of oligodendroglia in severe mental illness. Brain Research Bulletin 55, 597-610.
55. Wan C, Yang Y, Feng G, Gu N, Liu H, Zhu S, He L, Wang L (2005). Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neuroscience Letters 388, 126-131.
56. Wang F, Sun Z, Cui L, Du X, Wang X, Zhang H, Cong Z, Hong N, Zhang D (2004). Anterior cingulum abnormalities in male patients with schizophrenia determined through diffusion tensor imaging. American Journal of Psychiatry 161, 573-575.
57. Weiss MD, Hammer J, Quarles RH (2000). Oligodendrocytes in aging mice lacking myelin-associated glycoprotein are dystrophic but not apoptotic. Journal of Neuroscience Research 62, 772-780.
58. Weiss MD, Luciano CA, Quarles RH (2001). Nerve conduction abnormalities in aging mice deficient for myelin-associated glycoprotein. Muscle and Nerve 24, 1380-1387.
59. Zai G, King N, Wigg K, Couto J, Wong GWH, Honer WG, Barr CL, Kennedy JL (2005). Genetic study of the myelin oligodendrocyte glycoprotein (MOG) gene in schizophrenia. Genes, Brain and Behavior 4, 2-9.